Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

Part of paid clinical trials in Mesa, Arizona.

Sponsor
Hanmi Pharmaceutical Company Limited
Study ID
NCT07527650
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • HM15275 — DRUG
    HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
  • Placebo of HM15275 — DRUG
    A sterile, matching solution supplied in pre-filled syringes.

Study Details

This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

Key Dates

First listed
Apr 14, 2026
Start date
May 18, 2026
Status verified
Jun 2026
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HM15275
    Participants will receive HM15275 via subcutaneous (SC) injection.
  • Placebo Comparator: Placebo of HM15275
    Participants will receive placebo of HM15275 via subcutaneous (SC) injection.

Primary Outcome Measure

Change in Glycated Hemoglobin (HbA1c) [ Time Frame: Up to 41 weeks ]

Central Contacts

Locations (14)

FacilityCityStateZIPSite coordinators
Desert Clinical ResearchMesaArizona85123
Gerald Shockey (PRINCIPAL_INVESTIGATOR)
Accel Research Sites - DeLandDeLandFlorida32720
Bruce Rankin (PRINCIPAL_INVESTIGATOR)
AdventHealth Translational Research InstituteOrlandoFlorida32804
Richard Edwin Pratley (PRINCIPAL_INVESTIGATOR)
Charter ResearchOrlandoFlorida32803
Mary Hilal Quarterman (PRINCIPAL_INVESTIGATOR)
Centricity Research IRT - DBA IACT Health Columbus PiedmontColumbusGeorgia31904
Steven Leichter (PRINCIPAL_INVESTIGATOR)
The South Bend ClinicSouth BendIndiana46617
Rita Schmid (PRINCIPAL_INVESTIGATOR)
Jefferson City Medical CenterJefferson CityMissouri65109
Benjamin Cook (PRINCIPAL_INVESTIGATOR)
Clay Platte Family MedicineKansas CityMissouri64151
Scott Kuennen (PRINCIPAL_INVESTIGATOR)
Methodist Physicians ClinicFremontNebraska68025
Thomas Wolf (PRINCIPAL_INVESTIGATOR)
Santa Rosa Medical Centers of NevadaLas VegasNevada89119
Syed Pervaiz (PRINCIPAL_INVESTIGATOR)
Lucas Research, Inc.Morehead CityNorth Carolina28557
Kathryn Jean Lucas (PRINCIPAL_INVESTIGATOR)
Centricity Research ColumbusColumbusOhio43213
Sridhar Guduri (PRINCIPAL_INVESTIGATOR)
Olympus Family MedicineSalt Lake CityUtah84117
Jared Probst (PRINCIPAL_INVESTIGATOR)
Manassas Clinical Research CenterManassasVirginia20110
Nabil Saleh Andrawis (PRINCIPAL_INVESTIGATOR)

Find similar trials in Mesa, AZ

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials
By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Desert Clinical Research· Mesa, AZAccel Research Sites - DeLand· DeLand, FLAdventHealth Translational Research Institute· Orlando, FLCharter Research· Orlando, FLCentricity Research IRT - DBA IACT Health Columbus Piedmont· Columbus, GAThe South Bend Clinic· South Bend, IN

Related Studies